New Class of Adjuvants Enables Lower Dosing of Colistin Against Acinetobacter baumannii

Antibiotic resistance has become increasingly prevalent over the past few decades, and this combined with a dearth in the development of new classes of antibiotics to treat multidrug resistant Gram-negative infections has led to a significant global health problem and the increased usage of colistin...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	ACS infectious diseases 2018-09, Vol.4 (9), p.1368-1376
Hauptverfasser:	Minrovic, Bradley M., Jung, David, Melander, Roberta J., Melander, Christian
Format:	Artikel
Sprache:	eng
Schlagworte:	Acinetobacter baumannii - drug effects Acinetobacter baumannii - physiology Acinetobacter Infections - drug therapy Acinetobacter Infections - microbiology Adjuvants, Pharmaceutic - pharmacology Animals Anti-Bacterial Agents - pharmacology Colistin - pharmacology Drug Synergism Humans Imidazoles - pharmacology Moths
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!